Lv64
2360 积分 2022-03-21 加入
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study
1个月前
已完结
Ovarian cancer metastasis: Looking beyond the surface
2个月前
已关闭
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
2个月前
已关闭
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
2个月前
已关闭
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
2个月前
已完结
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
2个月前
已完结
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
2个月前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
2个月前
已完结
Quantitative Membrane Proteomics for Discovery of Actionable Drug Targets at the Surface of RAS-Driven Human Cancer Cells
2个月前
已关闭
HP-β-CD for the formulation of IgG and Ig-based biotherapeutics
2个月前
已关闭
皖公网安备34019202002308
